ERA is in the process of being migrated to Scholaris, a Canadian shared institutional repository service (https://scholaris.ca). Deposits and changes to existing ERA items and collections are frozen until migration is complete. Please contact erahelp@ualberta.ca for further assistance
Communities and Collections
Usage
- 241 views
- 420 downloads
Newborn blood spot screening for galactosemia, tyrosinemia type I, homocystinuria, sickle cell anemia, sickle cell/beta-thalassemia, sickle cell/hemoglobin C disease, and severe combined immunodeficiency
-
- Author(s) / Creator(s)
-
This STE report examines the safety, screening accuracy, therapeutic efficacy/effectiveness, cost-effectiveness, budget impact, and health system readiness of newborn screening for seven conditions (galactosemia, tyrosinemia type I, homocystinuria, sickle cell anemia, sickle cell/beta-thalassemia, sickle cell/hemoglobin C disease, and severe combined immunodeficiency), contextualized to the Alberta setting.
-
- Date created
- 2016-03-23
-
- Subjects / Keywords
-
- Type of Item
- Report